Your browser is no longer supported. Please, upgrade your browser.
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E17.58 EPS (ttm)4.07 Insider Own0.10% Shs Outstand1.25B Perf Week0.87%
Market Cap89.43B Forward P/E10.66 EPS next Y6.72 Insider Trans-4.27% Shs Float1.25B Perf Month-0.49%
Income5.16B PEG13.52 EPS next Q1.68 Inst Own81.60% Short Float1.79% Perf Quarter7.51%
Sales26.64B P/S3.36 EPS this Y-97.70% Inst Trans1.52% Short Ratio3.69 Perf Half Y11.09%
Book/sh15.70 P/B4.56 EPS next Y-5.69% ROA7.80% Target Price75.99 Perf Year10.10%
Cash/sh5.22 P/C13.71 EPS next 5Y1.30% ROE27.80% 52W Range56.56 - 73.34 Perf YTD22.91%
Dividend2.84 P/FCF18.10 EPS past 5Y-61.80% ROI5.00% 52W High-2.36% Beta0.42
Dividend %3.97% Quick Ratio1.20 Sales past 5Y-5.40% Gross Margin80.10% 52W Low26.61% ATR1.20
Employees13600 Current Ratio1.40 Sales Q/Q20.90% Oper. Margin36.70% RSI (14)52.95 Volatility1.84% 1.52%
OptionableYes Debt/Eq1.53 EPS Q/Q145.40% Profit Margin19.40% Rel Volume1.78 Prev Close71.33
ShortableYes LT Debt/Eq1.42 EarningsJul 29 AMC Payout67.60% Avg Volume6.09M Price71.61
Recom2.40 SMA20-0.08% SMA501.97% SMA2008.25% Volume10,814,832 Change0.39%
Jul-30-21Reiterated RBC Capital Mkts Outperform $81 → $84
Jul-30-21Reiterated BMO Capital Markets Market Perform $67 → $72
Apr-01-21Upgrade Bernstein Mkt Perform → Outperform $80
Mar-30-21Upgrade Redburn Neutral → Buy
Jan-19-21Upgrade Morgan Stanley Equal-Weight → Overweight $83
Jan-04-21Upgrade Guggenheim Neutral → Buy
Nov-03-20Resumed Morgan Stanley Equal-Weight $67
Oct-28-20Initiated UBS Neutral $61
Sep-30-20Resumed Jefferies Buy $78
Sep-15-20Upgrade Maxim Group Hold → Buy $88
Jul-31-20Reiterated Wells Fargo Equal Weight $87 → $76
Jul-31-20Reiterated SunTrust Hold $73 → $74
Jul-31-20Reiterated RBC Capital Mkts Outperform $89 → $87
Jul-31-20Reiterated Piper Sandler Overweight $90 → $85
Jul-31-20Reiterated Morgan Stanley Equal-Weight $80 → $79
Jul-31-20Reiterated Credit Suisse Neutral $75 → $73
Jul-20-20Upgrade Credit Suisse Underperform → Neutral $64 → $75
Jun-03-20Upgrade SVB Leerink Mkt Perform → Outperform $85 → $94
May-26-20Upgrade SunTrust Sell → Hold $73
May-01-20Downgrade SunTrust Hold → Sell $70
Sep-17-21 04:41PM  
03:59PM  
03:56PM  
02:09PM  
Sep-16-21 12:49PM  
07:00AM  
07:00AM  
Sep-15-21 01:51PM  
Sep-13-21 05:50PM  
01:40PM  
08:30AM  
Sep-09-21 04:16PM  
02:24PM  
Sep-08-21 01:37PM  
Sep-07-21 02:12PM  
Sep-03-21 01:58PM  
Sep-02-21 05:50PM  
02:18PM  
Sep-01-21 04:05PM  
02:14PM  
Aug-31-21 04:37PM  
01:25PM  
Aug-30-21 02:06PM  
05:52AM  
Aug-27-21 02:07PM  
Aug-26-21 02:37PM  
11:47AM  
11:43AM  
Aug-25-21 01:38PM  
Aug-24-21 02:16PM  
01:21PM  
01:16PM  
Aug-23-21 01:57PM  
Aug-20-21 02:54PM  
11:57AM  
10:25AM  
Aug-19-21 04:15PM  
03:01PM  
Aug-18-21 02:06PM  
10:10AM  
08:51AM  
Aug-17-21 03:54PM  
Aug-16-21 01:50PM  
Aug-15-21 05:35AM  
Aug-13-21 02:05PM  
Aug-12-21 04:02PM  
02:11PM  
Aug-11-21 02:20PM  
08:51AM  
08:00AM  
Aug-09-21 02:16PM  
12:49PM  
10:49AM  
Aug-06-21 03:15PM  
02:08PM  
Aug-05-21 05:13PM  
01:47PM  
08:30AM  
06:02AM  
Aug-04-21 02:12PM  
07:00AM  
Aug-03-21 02:25PM  
11:51AM  
10:45AM  
03:33AM  
Aug-02-21 01:55PM  
Jul-31-21 08:02AM  
Jul-30-21 01:56PM  
01:12PM  
09:32AM  
04:01AM  
Jul-29-21 05:25PM  
05:05PM  
04:30PM  
04:14PM  
04:01PM  
02:06PM  
Jul-28-21 03:45PM  
01:51PM  
Jul-27-21 02:12PM  
11:32AM  
11:02AM  
Jul-26-21 03:59PM  
Jul-23-21 01:53PM  
Jul-22-21 03:03PM  
02:36PM  
11:10AM  
06:31AM  
Jul-21-21 05:50PM  
01:43PM  
11:22AM  
Jul-20-21 04:01PM  
02:51PM  
Jul-19-21 02:01PM  
08:50AM  
08:00AM  
06:17AM  
06:06AM  
Jul-17-21 06:01AM  
06:01AM  
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wilfong Diane E.SVP, Controller & CAOAug 17Option Exercise68.0813,610926,53634,008Aug 18 07:32 PM
Wilfong Diane E.SVP, Controller & CAOAug 17Sale72.5013,610986,72520,398Aug 18 07:32 PM
Mercier JohannaChief Commercial OfficerMay 04Sale66.0919,4961,288,5478,068May 05 05:02 PM
Whitley Richard JamesDirectorMay 03Option Exercise20.6420,282418,72251,404May 04 06:37 PM
Whitley Richard JamesDirectorMay 03Sale64.5720,2821,309,65531,122May 04 06:37 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 11Sale63.361,48694,15329,166Mar 12 06:39 PM
Wilfong Diane E.SVP, Controller & CAOFeb 10Option Exercise0.00778017,606Feb 11 05:58 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Sale67.411,975133,13528,832Feb 11 05:56 PM
Wilfong Diane E.SVP, Controller & CAOFeb 06Option Exercise0.001,866017,361Feb 09 07:46 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise0.002,728031,560Feb 09 07:44 PM
Dickinson Andrew DEVP, Chief Financial OfficerFeb 06Option Exercise0.001,818033,081Feb 09 07:41 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 01Sale65.979,711640,63328,832Feb 03 06:23 PM
Lofton Kevin EDirectorJan 22Option Exercise20.6420,282418,72274,203Jan 25 01:55 PM
Whitley Richard JamesDirectorOct 01Option Exercise0.001,434031,122Oct 05 07:09 PM